Definium Therapeutics (NASDAQ:DFTX) Shares Down 5.6% – Here’s What Happened

Definium Therapeutics, Inc. (NASDAQ:DFTX)’s stock price dropped 5.6% during trading on Tuesday . The stock traded as low as $37.93 and last traded at $38.01. Approximately 804,683 shares were traded during trading, a decline of 64% from the average session volume of 2,245,351 shares. The stock had previously closed at $40.25.

Key Definium Therapeutics News

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Second Phase 3 success: Definium reported that its Panorama Phase 3 study of DT120 ODT met its primary endpoint in generalized anxiety disorder, with statistically significant improvements in anxiety symptoms. The result strengthens the case for the company’s LSD-based treatment and supports planned discussions with the FDA ahead of a potential 2027 regulatory filing. Definium Reports Second Phase III Success in Anxiety Disorder Program
• Positive Sentiment: Analysts remain bullish: Robert W. Baird raised its price target to $79 from $75 and maintained an “outperform” rating. Needham and HC Wainwright also reaffirmed “buy” ratings with price targets of $66 and $70, respectively, implying substantial potential upside if DT120 advances successfully.
• Positive Sentiment: Coverage characterized the Phase 3 outcome as potentially “unprecedented” anxiety data and argued that DFTX could still be undervalued despite the recent move, increasing expectations for the drug’s commercial opportunity. Definium Therapeutics After Its Phase 3 Win Still Looks Undervalued
• Neutral Sentiment: Unusually heavy put-option activity, with 6,567 puts purchased versus typical daily volume of 3,899, indicates increased hedging or bearish speculation, although it does not establish the direction of the stock.
• Negative Sentiment: After the initial rally, profit-taking and heightened expectations appear to be weighing on shares. Definium remains an unprofitable clinical-stage biotech, and regulatory, commercialization, and execution risks remain ahead of any FDA decision.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on DFTX. Citigroup reissued a “buy” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Friday, July 17th. JonesTrading increased their target price on Definium Therapeutics from $74.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. UBS Group reiterated a “buy” rating and set a $70.00 target price on shares of Definium Therapeutics in a research report on Tuesday. Finally, Wall Street Zen lowered shares of Definium Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $64.88.

Definium Therapeutics Trading Down 8.0%

The firm has a market capitalization of $4.98 billion, a PE ratio of -10.80 and a beta of 2.23. The stock’s 50-day moving average price is $42.92 and its 200 day moving average price is $30.49. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.95 and a quick ratio of 6.95.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.89). On average, sell-side analysts expect that Definium Therapeutics, Inc. will post -3.02 EPS for the current fiscal year.

Insider Transactions at Definium Therapeutics

In other Definium Therapeutics news, insider Matthew Wiley sold 2,867 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $129,101.01. Following the completion of the sale, the insider directly owned 174,633 shares in the company, valued at approximately $7,863,723.99. This represents a 1.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Brandi Roberts sold 3,013 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $135,675.39. Following the transaction, the chief financial officer directly owned 209,487 shares in the company, valued at $9,433,199.61. The trade was a 1.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 67,119 shares of company stock valued at $2,887,496. Company insiders own 2.40% of the company’s stock.

Institutional Trading of Definium Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP bought a new position in Definium Therapeutics during the 2nd quarter worth about $138,755,000. Avoro Capital Advisors LLC bought a new stake in shares of Definium Therapeutics in the 4th quarter valued at about $66,950,000. Bank of New York Mellon Corp lifted its position in shares of Definium Therapeutics by 3.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 777,271 shares of the company’s stock worth $36,563,000 after purchasing an additional 24,349 shares during the period. UBS Group AG boosted its stake in shares of Definium Therapeutics by 23.9% during the fourth quarter. UBS Group AG now owns 683,802 shares of the company’s stock valued at $9,156,000 after purchasing an additional 131,993 shares in the last quarter. Finally, Seven Fleet Capital Management LP bought a new position in shares of Definium Therapeutics during the second quarter valued at approximately $6,992,000. 27.91% of the stock is owned by hedge funds and other institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.